Fundraising Fox

Trefoil Therapeutics

San Diego, US · Founded 2016 · Delaware corporation · 9 known investors

Find your way into Trefoil Therapeutics

237 people in our graph share verified history with the Trefoil Therapeutics team — schools, employers, funds. One of them is your warm intro.

Vincent Roseunlockedknows David Eveleth · together at Bayer
×6knows the team · via University of Connecticut
×5knows the team · via Bayer

Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases. Its lead investigational candidate, TTHX1114, is being studied in a Phase 2 trial for improving visual recovery after Descemet Stripping Only (DSO) procedures.

BiotechHealthtechMedical Devices

Founders & leadership

Trefoil Therapeutics was founded in 2016 by David Eveleth.

DEDavid Eveleth
David EvelethinPresident, CEO and Founder2013–2025David Eveleth founded Trefoil Therapeutics, a clinical-stage biotech company developing regenerative therapies for corneal diseases, and has over 30 years of experience in ophthalmology, neuroscience, and regenerative medicine across scientific and commercial roles.
SNSchalon Newton
Schalon NewtoninChief Business Officer2015–2024

Board

CSChristy Shaffer
Christy ShafferinChair of the Board of Directors
RB
Ralph BradshawBoard director

Investors · 9

ExSight Ventures✓ verifiedNew York
Hatteras Venture Partners✓ verifiedResearch Triangle · $500K – $4M
Solasta Ventures✓ verifiedBoston
Access Biotechnology✓ verifiedNew York City
Bios Partners✓ verifiedFort Worthvia Stella Robertson · board
Correlation Ventures✓ verifiedSan Francisco · $100K – $4M
FemHealth Ventures✓ verifiedShort Hills
InFocus Capital Partners, LLC✓ verifiedJericho
Bios ClinicalreportedFort Worth

Funding

SEC filings, press & company announcements

$33.3M disclosed across 4 of 5 rounds · 2016–2025

▶$4.6MraisedMay 2025 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christy ShafferDirector
  • Stella RobertsonDirector
  • Jonathan MowExecutive Officer
  • Ben McGrawDirector
  • John FucciDirector
  • Kseniya SimpsonDirector
Offering amount
$5M
Amount sold
$4.6M
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedMar 2022 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christy ShafferDirector
  • Derek YoonDirector
  • Stella RobertsonDirector
  • Ben McGrawDirector
  • David EvelethExecutive Officer, Director
  • Schalon NewtonExecutive Officer
Offering amount
$12M
Amount sold
$12M
First sale
Mar 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.6MraisedAug 2019 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christy ShafferDirector
  • Derek YoonDirector
  • Stella RobertsonDirector
  • Schalon NewtonExecutive Officer
  • David EvelethExecutive Officer, Director
  • Ben McGrawDirector
Offering amount
$28M
Amount sold
$12.6M
First sale
Jul 2019
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.2MraisedDec 2016 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ralph BradshawDirector
  • Christy ShafferDirector
  • Schalon NewtonExecutive Officer
  • David EvelethExecutive Officer, Director
Offering amount
$5.2M
Amount sold
$4.2M
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Medscape11 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Trefoil Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

News | Hatteras Venture Partners Healthcare Insightshatterasvp.com · Jan 2026Trefoil Therapeutics Announces Third Tranche of $28 Million Series A Financing Based on Achievement of Clinical Trial Objectives | Business Wirebusinesswire.com · Dec 2021Trefoil Therapeutics banks $28M to create first drug for genetic eye disorder | Fierce Biotechfiercebiotech.com · Jul 2019Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseasesglobenewswire.com · Jul 2019Trefoil Therapeutics Raises $28M in Series A Funding - FinSMEsfinsmes.com · Jul 2019Trefoil Therapeutics secures $5.2 million in financinghealio.com · Jan 2017

Frequently asked questions

What does Trefoil Therapeutics do?
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases. Its lead investigational candidate, TTHX1114, is being studied in a Phase 2 trial for improving visual recovery after Descemet Stripping Only (DSO) procedures.
Who founded Trefoil Therapeutics?
Trefoil Therapeutics was founded by David Eveleth in 2016.
Who are Trefoil Therapeutics's investors?
Trefoil Therapeutics's investors include ExSight Ventures, Hatteras Venture Partners, Solasta Ventures, Access Biotechnology, Bios Partners, Correlation Ventures, FemHealth Ventures, InFocus Capital Partners, LLC and 1 more.
How much funding has Trefoil Therapeutics raised?
Trefoil Therapeutics has disclosed $33.3M raised across 4 of its 5 known rounds.
Where is Trefoil Therapeutics headquartered?
Trefoil Therapeutics is headquartered in San Diego, US.